Reduction of urinary levels of N-telopeptide correlates with treatment compliance in women with postmenopausal osteoporosis receiving alendronate

Menopause

Volumn 19, Issue 1, 2012, Pages 67-74

  Palacios, Santiago ^a   Neyro, José Luis ^b   Ferrer, Javier ^c   Villero, José ^d   Cañada, Enrique ^e   Redondo, Esther ^f   Caloto, Ma Teresa ^g   Nocea, Gonzalo ^g  

^a Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f Centro Monográfico de la Mujer   (Spain)

^g Medical affairs Merck sharp and Dohme ltd   (Spain)

Author keywords

Alendronate; Effectiveness; N telopeptide; Osteoporosis; Postmenopause; Treatment compliance

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; VITAMIN D;

ADULT; ARTICLE; BONE TURNOVER; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME; URINARY EXCRETION; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COLLAGEN TYPE I; FEMALE; HUMANS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDES; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84655161477     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e3182214f5a     Document Type: Article

References (64)

1. Bergmann P. Clinical use of biological markers of bone turnover in osteoporosis [in French]. Rev Med Brux 2008;29:295-300.
2. National Osteoporosis Foundation. Osteoporosis facts [NOF Web site]. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed March 26, 2010.
3. Compston J. Clinical and therapeutic aspects of osteoporosis. Eur J Radiol 2009;71:388-391.
4. Cole Z, Dennison E, Cooper C. Update on the treatment of postmenopausal osteoporosis. Br Med Bull 2008;86:129-143.
5. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85: 231-236. (Pubitemid 32268819)
6. Hochberg MC, Greenspan S, Wasnich RD, et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592. (Pubitemid 34615244)
7. Hochberg MC, Ross PD, Black D, et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with post-menopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 1999;42:1246-1254. (Pubitemid 29268962)
8. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, nonspine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 2004;19:1250-1258. (Pubitemid 41094365)
9. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-289. (Pubitemid 34219441)
10. Li Z, Meredith MP, Hoseyni MS. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat Med 2001;20: 3175-3188. (Pubitemid 33034879)
11. Marcus R, Wong M, Heath H III, et al. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocr Rev 2002;23:16-37. (Pubitemid 34185305)
12. Delmas PD, Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy. Bone 2004;34:599-604. (Pubitemid 38393794)
13. Miller PD, Hochberg MC, Wehren LE, et al. How useful are measures of BMD and bone turnover? Curr Med Res Opin 2005;21:545-553. (Pubitemid 40676106)
14. Pérez-López FR. Postmenopausal osteoporosis and alendronate. Maturitas 2004;48:179-192. (Pubitemid 38781143)
15. Reid DM, Hosking D, Kendler D, et al. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS-international. Clin Drug Investig 2006;26:63-74. (Pubitemid 43275700)
16. Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int 2005;16:842-848. (Pubitemid 40933602)
17. Miller PD. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Curr Osteoporos Rep 2005;3:103-110.
18. Garnero P. Bone markers in osteoporosis. Curr Osteoporos Rep 2009; 7:84-90.
19. Ravn P, Clemmesen B, Christiansen C. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 1999;24:237-244. (Pubitemid 29094566)
20. Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica. Reumatol Clin 2007;3:26-32.
21. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE. Potential for bone turnover markers to cost-effectively identify and select post-menopuasal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 2007;18:201-210. (Pubitemid 46090224)
22. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol 2008;61:577-587. (Pubitemid 351678208)
23. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res 1998;13:1431-1438. (Pubitemid 28418909)
24. Iwamoto J, Takeda T, Sato Y, Uzawa M. Early changes in urinary crosslinked N-terminal telopeptides of type I collagen level correlate with one-year response of lumbar bone mineral density to alendronate in Japanese postmenopausal women with osteoporosis. J Bone Miner Metab 2005;23:238-242. (Pubitemid 40603207)
25. Ravn P, Hosking D, Thompson D, et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 1999;84:2363-2368.
26. Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006;91:1370-1375.
27. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18:1051-1056. (Pubitemid 37294942)
28. Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Med J 2009;50:474-481.
29. Bauer DC, Garnero P, Hochberg MC, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 2006;21:292-299. (Pubitemid 43265295)
30. Seibel MJ, Naganathan V, Barton I, Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 2004;19:323-329. (Pubitemid 38116747)
31. Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 2006;39:237-243. (Pubitemid 43851376)
32. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate therapy. J Clin Endocrinol Metab 1999;79:1693-1700.
33. Ravn P, Clemmesen B, Riis BJ, Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;19:527-533.
34. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone mineral density but without vertebral fractures. JAMA 1998;280:2077-2080.
35. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-1352. (Pubitemid 29483192)
36. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis Int 2000;11:83-91. (Pubitemid 30099515)
37. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle JC. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporosis Int 2000;11:295-303. (Pubitemid 30417181)
38. Eastell R, Mallinak N, Weiss S, et al. Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res 2000;15:594-598. (Pubitemid 30134105)
39. Ju HS, Leung S, Brown B, et al. Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 1997;43:1570-1576. (Pubitemid 27396349)
40. Iwamoto J, Miyata A, Sato Y, Takeda T, Matsumoto H. Five-year alendronate treatment outcome in older postmenopausal Japanese women with osteoporosis or osteopenia and clinical risk factors for fractures. Ther Clin Risk Manag 2009;5:773-779.
41. Eisman JA, Rizzoli R, Roman-Ivorra J, et al. Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study. Curr Med Res Opin 2004;20:699-705. (Pubitemid 38685015)
42. Braga A, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 1999;14:602-608. (Pubitemid 29153394)
43. Chailurkit L, Jongjaroenprasert W, Rungbunnapun S, Ongphiphadhanakul B, Sae-Tung S, Rajatanavin R. Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 2003;21:421-427. (Pubitemid 38017700)
44. Sambrook PN, Geusens P, Ribot C, et al. Alendronate produces greater effects than raloxifene on bone dessity and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International. J Int Med 2004;255:503-511. (Pubitemid 38446364)
45. Takada J, Iba K, Imoto K, Yamashita T. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate. J Bone Miner Metab 2007;25:142-146. (Pubitemid 46328670)
46. De Papp AE, Bone HG, Caufield MP, et al. A cross-sectional study of bone turnover markers in healthy premenopausal women. Bone 2007;40:1222-1230. (Pubitemid 46550988)
47. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282: 1344-1352. (Pubitemid 29483192)
48. Bauer DC, Black DM, Garnero P, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-1258. (Pubitemid 41094365)
49. Chesnut CH, Bell NH, Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37. (Pubitemid 27089984)
50. Bagger YZ, Tankó LB, Alexandersen P, Ravn P, Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-307. (Pubitemid 37103246)
51. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-982.
52. Delmas PD, Muñoz F, Black DM, et al. Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 2009;24:1544-1551.
53. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. Obstet Gynecol 2009;114:999-1007.
54. Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Delmas PD. Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 2005;20:1813-1819. (Pubitemid 41361882)
55. Wainwright SA, Marshall LM, Ensrud KE, et al. Hip fracture in women without osteoporosis J Clin Endocrinol Metab 2005;90:2787-2793. (Pubitemid 40686325)
56. Menopause and osteoporosis update 2009. Available at: http://www.sogc.org/guidelines/documents/Menopause-JOGC-Jan-09.pdf. Accessed July 11, 2009.
57. Drake WM, Kendler DL, Rosen CJ, Orwoll ES. An investigation of the predictors of bone mineral density and response to therapy with alendronate in osteoporotic men. J Clin Endocrinol Metab 2003;88: 5759-5765. (Pubitemid 38033047)
58. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P. Prediction of bone loss using biochemical markers of bone turnover. Osteoporos Int 2007;18: 1297-1305. (Pubitemid 47300283)
59. Reginster JY, Deroisy R, Collete J, Albert A, Zegels B. Prediction of bone loss rate in healthy postmenopausal women. Calcif Tissue Int 1997;60:261-264. (Pubitemid 27106250)
60. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas PD. Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999;14:1614-1621. (Pubitemid 29416689)
61. Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res 2000;15: 1398-1404. (Pubitemid 30413874)
62. Garnero P, Munoz F, Sornay-Rendu E, Delmas PD. Associations of vitamin D status with bone mineral density, bone turnover, bone loss and fracture risk in healthy postmenopausal women. the OFELY study. Bone 2007;40:716-722. (Pubitemid 46201944)
63. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 2000;15:1526-1536. (Pubitemid 30484522)
64. Gorai I, Taguchi Y, Chaki O, Nakayama M, Minaguchi H. Specific changes of urinary excretion of cross-linked N-telopeptides of type I collagen in pre- and postmenopausal women: correlation with other markers of bone turnover. Calcif Tissue Int 1997;60:317-322. (Pubitemid 27143442)